返回 Agenda
Closing Session: Panel Discussion
Session Chair(s)
James D. Thompson, PhD
CMC Therapeutic Area Lead
Moderna Therapeutics , United States
This panel discussion is meant to highlight the challenges and issues with the development of oligonucleotide-based products in general, and as brought forth at this conference. The intention is to transform this discussion into action-oriented objectives to address the regulatory and industry issues and challenges affecting us all.
Speaker(s)
Session Co-Chair
James Wild, PhD
FDA, United States
Pharmacologist, CDER
Panelist
Emily Place, PhD, MPH
Biologics Consulting, United States
Senior Consultant
Panelist
Jeffery Engelhardt, DVM, PhD
Ionis Pharmaceuticals, Inc., United States
Vice President, Pathology and Nonclinical Drug Safety
Panelist
Arthur M. Krieg, MD
Checkmate Pharmaceuticals, United States
CEO and CSO
Panelist
Arthur A. Levin, PhD
Avidity Biosciences , United States
CSO
Panelist
Daniel Capaldi, PhD
Ionis Pharmaceuticals, Inc, United States
Vice President, Analytical and Process Development
Panelist
Kim Tyndall
CMC Tyndall Consultant LLC, United States
President